Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut R Mäcke

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Candidates for peptide receptor radiotherapy today and in the futureJean Claude Reubi, Helmut R Mäcke, Eric P Krenning
Nature Reviews. Urology|March 20, 2013
Targeting GRPR in urological cancers--from basic research to clinical applicationRosalba Mansi, Achim Fleischmann, Helmut R Mäcke, et al.
European Journal of Pharmacology|November 27, 2002
A new peptidic somatostatin agonist with high affinity to all five somatostatin receptorsJean Claude Reubi, Klaus-Peter Eisenwiener, Hans Rink, et al.
Molecular Imaging and Biology|September 23, 2003
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumorsJörg Kowalski, Marcus Henze, Jochen Schuhmacher, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|August 31, 2002
From monomers to micelles: investigation of the parameters influencing proton relaxivityGaëlle M Nicolle, Eva Tóth, Klaus-Peter Eisenwiener, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2007
68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDGAntonia Dimitrakopoulou-Strauss, Peter Hohenberger, Uwe Haberkorn, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumorsCecilia Hindorf, Sarah Chittenden, Louise Causer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2005
Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?Daniel Storch, Martin Béhé, Martin A Walter, et al.
Cancer|January 11, 2005
Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapyDaniel Beutler, Pierino Avoledo, Jean-Claude Reubi, et al.
Molecular Endocrinology (Baltimore, Md.)|November 14, 2009
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathwaysRenzo Cescato, Kimberly A Loesch, Beatrice Waser, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Candidates for peptide receptor radiotherapy today and in the futureJean Claude Reubi, Helmut R Mäcke, Eric P Krenning
Nature Reviews. Urology|March 20, 2013
Targeting GRPR in urological cancers--from basic research to clinical applicationRosalba Mansi, Achim Fleischmann, Helmut R Mäcke, et al.
European Journal of Pharmacology|November 27, 2002
A new peptidic somatostatin agonist with high affinity to all five somatostatin receptorsJean Claude Reubi, Klaus-Peter Eisenwiener, Hans Rink, et al.
Molecular Imaging and Biology|September 23, 2003
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumorsJörg Kowalski, Marcus Henze, Jochen Schuhmacher, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|August 31, 2002
From monomers to micelles: investigation of the parameters influencing proton relaxivityGaëlle M Nicolle, Eva Tóth, Klaus-Peter Eisenwiener, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2007
68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDGAntonia Dimitrakopoulou-Strauss, Peter Hohenberger, Uwe Haberkorn, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumorsCecilia Hindorf, Sarah Chittenden, Louise Causer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2005
Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?Daniel Storch, Martin Béhé, Martin A Walter, et al.
Cancer|January 11, 2005
Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapyDaniel Beutler, Pierino Avoledo, Jean-Claude Reubi, et al.
Molecular Endocrinology (Baltimore, Md.)|November 14, 2009
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathwaysRenzo Cescato, Kimberly A Loesch, Beatrice Waser, et al.
Pageof 3